Sabril

Sabril is a brand name of vigabatrin, approved by the FDA in the following formulation(s):

SABRIL (vigabatrin - for solution; oral)

• 
  Manufacturer: LUNDBECK INC
  
  Approval date: August 21, 2009
  
  Strength(s): 500MG/PACKET ^[RLD]

SABRIL (vigabatrin - tablet; oral)

• 
  Manufacturer: LUNDBECK INC
  
  Approval date: August 21, 2009
  
  Strength(s): 500MG ^[RLD]

Has a generic version of Sabril been approved?

No. There is currently no therapeutically equivalent version of Sabril available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sabril. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Sabril.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 21, 2014 - NEW CHEMICAL ENTITY
  
  
  • August 21, 2016 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Sabril Consumer Information (Drugs.com)
• Sabril Consumer Information (Wolters Kluwer)
• Sabril Solution Consumer Information (Wolters Kluwer)
• Sabril Consumer Information (Cerner Multum)
• Sabril Advanced Consumer Information (Micromedex)
• Vigabatrin Consumer Information (Wolters Kluwer)
• Vigabatrin Oral Solution Consumer Information (Wolters Kluwer)
• Vigabatrin Solution Consumer Information (Wolters Kluwer)
• Vigabatrin Tablets Consumer Information (Wolters Kluwer)
• Vigabatrin Consumer Information (Cerner Multum)
• Vigabatrin Advanced Consumer Information (Micromedex)